These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

873 related items for PubMed ID: 25936321

  • 1. Specific Lipoprotein(a) apheresis attenuates progression of carotid intima-media thickness in coronary heart disease patients with high lipoprotein(a) levels.
    Ezhov MV, Safarova MS, Afanasieva OI, Pogorelova OA, Tripoten MI, Adamova IY, Konovalov GA, Balakhonova TV, Pokrovsky SN.
    Atheroscler Suppl; 2015 May; 18():163-9. PubMed ID: 25936321
    [Abstract] [Full Text] [Related]

  • 2. Specific Lp(a) apheresis: A tool to prove lipoprotein(a) atherogenicity.
    Pokrovsky SN, Afanasieva OI, Safarova MS, Balakhonova TV, Matchin YG, Adamova IYU, Konovalov GA, Ezhov MV.
    Atheroscler Suppl; 2017 Nov; 30():166-173. PubMed ID: 29096833
    [Abstract] [Full Text] [Related]

  • 3. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography.
    Safarova MS, Ezhov MV, Afanasieva OI, Matchin YG, Atanesyan RV, Adamova IY, Utkina EA, Konovalov GA, Pokrovsky SN.
    Atheroscler Suppl; 2013 Jan; 14(1):93-9. PubMed ID: 23357149
    [Abstract] [Full Text] [Related]

  • 4. Association of lipoprotein(a) level with short- and long-term outcomes after CABG: The role of lipoprotein apheresis.
    Ezhov MV, Afanasieva OI, Il'ina LN, Safarova MS, Adamova IY, Matchin YG, Konovalov GA, Akchurin RS, Pokrovsky SN.
    Atheroscler Suppl; 2017 Nov; 30():187-192. PubMed ID: 29096836
    [Abstract] [Full Text] [Related]

  • 5. Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-lowering Therapy) study).
    Ikeda K, Takahashi T, Yamada H, Matsui K, Sawada T, Nakamura T, Matsubara H, (for the PEACE Investigators).
    Eur J Prev Cardiol; 2013 Dec; 20(6):1069-79. PubMed ID: 22689416
    [Abstract] [Full Text] [Related]

  • 6. Cascade plasma filtration during the first year after CABG in patients with hyperlipidemia refractory to statins.
    Ezhov MV, Il'ina LN, Safarova MS, Afanasieva OI, Adamova IY, Atanesyan RV, Konovalov GA, Akchurin RS, Pokrovsky SN.
    Atheroscler Suppl; 2013 Jan; 14(1):101-5. PubMed ID: 23357150
    [Abstract] [Full Text] [Related]

  • 7. Lipoprotein (a) levels are not associated with carotid plaques and carotid intima media thickness in statin-treated patients with familial hypercholesterolemia.
    Bos S, Duvekot MH, Touw-Blommesteijn AC, Verhoeven AJ, Mulder MT, Watts GF, Sijbrands EJ, Roeters van Lennep JE.
    Atherosclerosis; 2015 Sep; 242(1):226-9. PubMed ID: 26222903
    [Abstract] [Full Text] [Related]

  • 8. Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease.
    Kroon AA, van Asten WN, Stalenhoef AF.
    Ann Intern Med; 1996 Dec 15; 125(12):945-54. PubMed ID: 8967704
    [Abstract] [Full Text] [Related]

  • 9. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany.
    Heigl F, Hettich R, Lotz N, Reeg H, Pflederer T, Osterkorn D, Osterkorn K, Klingel R.
    Atheroscler Suppl; 2015 May 15; 18():154-62. PubMed ID: 25936320
    [Abstract] [Full Text] [Related]

  • 10. The impact of lipoprotein apheresis in patients with refractory angina and raised lipoprotein(a): Objectives and methods of a randomised controlled trial.
    Khan TZ, Pottle A, Pennell DJ, Barbir MS.
    Atheroscler Suppl; 2015 May 15; 18():103-8. PubMed ID: 25936312
    [Abstract] [Full Text] [Related]

  • 11. Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes.
    Hohenstein B, Julius U, Lansberg P, Jaeger B, Mellwig KP, Weiss N, Graehlert X, Roeder I, Ramlow W.
    Atheroscler Suppl; 2017 Nov 15; 30():180-186. PubMed ID: 29096835
    [Abstract] [Full Text] [Related]

  • 12. The Effect of Long-Term Atorvastatin Therapy on Carotid Intima-Media Thickness of Children With Dyslipidemia.
    Karapostolakis G, Vakaki M, Attilakos A, Marmarinos A, Papadaki M, Koumanidou C, Alexopoulou E, Gourgiotis D, Garoufi A.
    Angiology; 2021 Apr 15; 72(4):322-331. PubMed ID: 33242982
    [Abstract] [Full Text] [Related]

  • 13. Prevention of atherosclerosis progression using atorvastatin in normolipidemic coronary artery disease patients--a controlled randomized trial.
    Shukla A, Sharma MK, Jain A, Goel PK.
    Indian Heart J; 2005 Apr 15; 57(6):675-80. PubMed ID: 16521637
    [Abstract] [Full Text] [Related]

  • 14. Effects of Lipoprotein apheresis on the Lipoprotein(a) levels in the long run.
    Groß E, Hohenstein B, Julius U.
    Atheroscler Suppl; 2015 May 15; 18():226-32. PubMed ID: 25936330
    [Abstract] [Full Text] [Related]

  • 15. Lipoprotein (a) and coronary heart disease - is there an efficient secondary prevention?
    Mellwig KP, Horstkotte D, van Buuren F.
    Clin Res Cardiol Suppl; 2017 Mar 15; 12(Suppl 1):18-21. PubMed ID: 28233270
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
    Avellone G, Di Garbo V, Guarnotta V, Scaglione R, Parrinello G, Purpura L, Torres D, Campisi D.
    Int Angiol; 2010 Dec 15; 29(6):514-24. PubMed ID: 21173733
    [Abstract] [Full Text] [Related]

  • 17. The effects of simvastatin and levothyroxine on intima-media thickness of the carotid artery in female normolipemic patients with subclinical hypothyroidism: a prospective, randomized-controlled study.
    Duman D, Demirtunc R, Sahin S, Esertas K.
    J Cardiovasc Med (Hagerstown); 2007 Dec 15; 8(12):1007-11. PubMed ID: 18163011
    [Abstract] [Full Text] [Related]

  • 18. Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern.
    von Dryander M, Fischer S, Passauer J, Müller G, Bornstein SR, Julius U.
    Atheroscler Suppl; 2013 Jan 15; 14(1):39-44. PubMed ID: 23357139
    [Abstract] [Full Text] [Related]

  • 19. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study.
    Leebmann J, Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, Breitenberger P, Maerz W, Lehmacher W, Heibges A, Klingel R, Pro(a)LiFe Study Group*.
    Circulation; 2013 Dec 17; 128(24):2567-76. PubMed ID: 24056686
    [Abstract] [Full Text] [Related]

  • 20. LDL-apheresis in two patients with extremely elevated lipoprotein (a) levels.
    Bambauer R, Schiel R, Keller HE, Latza R.
    Int J Artif Organs; 1995 May 17; 18(5):286-90. PubMed ID: 8567105
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.